“Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis of heparin administration”. Eur. J. Clin. Invest.7 (1): 27–35. (1977). doi:10.1111/j.1365-2362.1977.tb01566.x. PMID65284.
“Molar antithrombin concentration in normal human plasma”. Haemostasis13 (6): 363–368. (1983). doi:10.1159/000214823. PMID6667903.
Jordan RE (1983). “Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism”. Arch. Biochem. Biophys.227 (2): 587–595. doi:10.1016/0003-9861(83)90488-5. PMID6607710.
“Regulation of thrombin activity by antithrombin and heparin”. Sem. Thromb. Hemost.20 (4): 373–409. (1994). doi:10.1055/s-2007-1001928. PMID7899869.
“Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin”. J. Mol. Biol.301 (5): 1287–1305. (2000). doi:10.1006/jmbi.2000.3982. PMID10966821.
“Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity”. J. Biol. Chem.276 (31): 29195–29199. (2001). doi:10.1074/jbc.M102187200. PMID11389142.
“Inhibition of the activated Cls subunit of the first component of complement by antithrombin III in the presence of heparin”. Thromb. Res.9 (3): 217–222. (1976). doi:10.1016/0049-3848(76)90210-3. PMID982345.
“Slow, spontaneous dissociation of the antithrombin-thrombin complex produces a proteolytically modified form of the inhibitor”. FEBS Lett119 (2): 241–244. (1980). doi:10.1016/0014-5793(80)80262-6. PMID7428936.
“Allosteric activation of antithrombin critically depends upon hinge region extension”. J. Biol. Chem.279 (45): 47288–47297. (2004). doi:10.1074/jbc.M408961200. PMID15326167.
“The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions”. Nature Structural & Molecular Biology1 (1): 48–54. (1994). doi:10.1038/nsb0194-48. PMID7656006.
“Synthesis of Thrombin inhibiting Heparin mimetics without side effects”. Nature398 (6726): 417–422. (1999). doi:10.1038/18877. PMID10201371.
“Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin”. Nature Structural & Molecular Biology11 (9): 857–862. (2004). doi:10.1038/nsmb811. PMID15311269.
“Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity”. J. Mol. Biol.326 (3): 823–833. (2003). doi:10.1016/S0022-2836(02)01382-7. PMID12581643.
“The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change”. Biochemistry36 (22): 6682–6691. (1997). doi:10.1021/bi9702492. PMID9184148.
“Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta”. Arterioscler. Thromb. Vasc. Biol.16 (10): 1292–1297. (1996). doi:10.1161/01.ATV.16.10.1292. PMID8857927.
“Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis”. Thromb. Haemost.70 (2): 361–369. (1993). doi:10.1055/s-0038-1649581. PMID8236149.
“A recurrent deletion in the antithrombin gene, AT106-108(-6 bp), identified by DNA heteroduplex detection”. Genomics16 (1): 298–299. (1993). doi:10.1006/geno.1993.1184. PMID8486379.
“A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop)”. Thromb. Res.64 (5): 621–625. (1991). doi:10.1016/S0049-3848(05)80011-8. PMID1808766.
“Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1”. Biochemistry36 (42): 13133–13142. (1997). doi:10.1021/bi970664u. PMID9335576.
“A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity”. J. Biol. Chem.276 (15): 11996–12002. (2001). doi:10.1074/jbc.M010170200. PMID11278631.
“Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor”. J. Biol. Chem.246 (11): 3712–3719. (1971). PMID4102937.
“Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis of heparin administration”. Eur. J. Clin. Invest.7 (1): 27–35. (1977). doi:10.1111/j.1365-2362.1977.tb01566.x. PMID65284.
“Molar antithrombin concentration in normal human plasma”. Haemostasis13 (6): 363–368. (1983). doi:10.1159/000214823. PMID6667903.
Jordan RE (1983). “Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism”. Arch. Biochem. Biophys.227 (2): 587–595. doi:10.1016/0003-9861(83)90488-5. PMID6607710.
“Regulation of thrombin activity by antithrombin and heparin”. Sem. Thromb. Hemost.20 (4): 373–409. (1994). doi:10.1055/s-2007-1001928. PMID7899869.
“Characterization of recombinant human antithrombin III synthesized in Chinese hamster ovary cells”. J. Biol. Chem.264 (35): 21153–21159. (1989). PMID2592368.
“Expression of biologically active human antithrombin III by recombinant baculovirus in Spodoptera frugiperda cells”. J. Biol. Chem.266 (6): 3995–4001. (1991). PMID1995647.
“Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin”. J. Mol. Biol.301 (5): 1287–1305. (2000). doi:10.1006/jmbi.2000.3982. PMID10966821.
“Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity”. J. Biol. Chem.276 (31): 29195–29199. (2001). doi:10.1074/jbc.M102187200. PMID11389142.
“Inhibition of the activated Cls subunit of the first component of complement by antithrombin III in the presence of heparin”. Thromb. Res.9 (3): 217–222. (1976). doi:10.1016/0049-3848(76)90210-3. PMID982345.
“Slow, spontaneous dissociation of the antithrombin-thrombin complex produces a proteolytically modified form of the inhibitor”. FEBS Lett119 (2): 241–244. (1980). doi:10.1016/0014-5793(80)80262-6. PMID7428936.
“Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites”. Biochemistry42 (27): 8143–8152. (2003). doi:10.1021/bi034363y. PMID12846563.
“The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin”. J. Biol. Chem.255 (21): 10081–10090. (1980). PMID6448846.
Griffith MJ (1982). “Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin”. J. Biol. Chem.257 (13): 7360–7365. PMID7085630.
“Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects”. J. Biol. Chem.266 (10): 6353–6354. (1991). PMID2007588.
“Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement”. J. Biol. Chem.267 (18): 12528–12538. (1992). PMID1618758.
“Allosteric activation of antithrombin critically depends upon hinge region extension”. J. Biol. Chem.279 (45): 47288–47297. (2004). doi:10.1074/jbc.M408961200. PMID15326167.
“The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions”. Nature Structural & Molecular Biology1 (1): 48–54. (1994). doi:10.1038/nsb0194-48. PMID7656006.
“Synthesis of Thrombin inhibiting Heparin mimetics without side effects”. Nature398 (6726): 417–422. (1999). doi:10.1038/18877. PMID10201371.
“Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin”. Nature Structural & Molecular Biology11 (9): 857–862. (2004). doi:10.1038/nsmb811. PMID15311269.
“Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity”. J. Mol. Biol.326 (3): 823–833. (2003). doi:10.1016/S0022-2836(02)01382-7. PMID12581643.
“The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change”. Biochemistry36 (22): 6682–6691. (1997). doi:10.1021/bi9702492. PMID9184148.
“Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta”. Arterioscler. Thromb. Vasc. Biol.16 (10): 1292–1297. (1996). doi:10.1161/01.ATV.16.10.1292. PMID8857927.
“Antithrombin and its inherited deficiency states”. Semin. Hematol.34 (3): 188–204. (1997). PMID9241705.
Sas G (1984). “Hereditary antithrombin III deficiency: biochemical aspects”. Haematologica17 (1): 81–86. PMID6724355.
“Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis”. Thromb. Haemost.70 (2): 361–369. (1993). doi:10.1055/s-0038-1649581. PMID8236149.
“A recurrent deletion in the antithrombin gene, AT106-108(-6 bp), identified by DNA heteroduplex detection”. Genomics16 (1): 298–299. (1993). doi:10.1006/geno.1993.1184. PMID8486379.
“A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop)”. Thromb. Res.64 (5): 621–625. (1991). doi:10.1016/S0049-3848(05)80011-8. PMID1808766.
“Molecular basis of inherited human antithrombin deficiency”. Blood80 (9): 2159–2171. (1992). PMID1421387.
“Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1”. Biochemistry36 (42): 13133–13142. (1997). doi:10.1021/bi970664u. PMID9335576.
“Formation of the antithrombin heterodimer in vivo and the onset of thrombosis”. Blood94 (10): 3388–3396. (1999). PMID10552948.
“A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity”. J. Biol. Chem.276 (15): 11996–12002. (2001). doi:10.1074/jbc.M010170200. PMID11278631.
